Cowen Downgrades Nivalis Therapeutics (NVLS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Raymond James Downgrades Nivalis Therapeutics (NVLS) to Market Perform
November 29, 2016 7:39 AM ESTRaymond James downgraded Nivalis Therapeutics (NASDAQ: NVLS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Nivalis Therapeutics click here. For more ratings news on Nivalis Therapeutics click here.
Shares of Nivalis Therapeutics closed at $6.25 yesterday.
... MoreStifel Downgrades Nivalis Therapeutics (NVLS) to Hold as Data Suggest No Meaningful Treatment Effect
November 29, 2016 6:19 AM ESTStifel downgraded Nivalis Therapeutics (NASDAQ: NVLS) from Buy to Hold with a price target of $3.25 (from $16.00) after the company released Phase II data for cavosonstat in the treatment of patients with homozygous F508del CF that were stably on Orkambi. Based on the... More
Baird Downgrades Nivalis Therapeutics (NVLS) to Neutral Following Clinical Failure
November 29, 2016 6:14 AM ESTBaird downgraded Nivalis Therapeutics (NASDAQ: NVLS) from Outperform to Neutral with a price target of $3.00 (from $29.00) after clinical trial failure.
Analyst Brian Skorney commented, "Nivalis announced that the company's flagship proof-of-concept study of cavosonstat in combination with Vertex's Orkambi failed to show an... More
Nivalis Therapeutics (NVLS) Announces Cavosonstat Phase 2 in CF Missed Primary Endpoint
November 28, 2016 4:06 PM ESTNivalis Therapeutics, Inc. (Nasdaq: NVLS) announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, 200 mg and 400 mg, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi. There were no dose limiting toxicities and cavosonstat was well tolerated at all doses in the trial. The trial failed, however, to demonstrate benefit in absolute change in percent predicted FEV1, the trials primary endpoint, or in sweat chloride reduction at 12... More
